ALK and non-small cell lung carcinoma: For example, testing an anaplastic lymphoma kinase (ALK) inhibitor in a small cohort of unselected patients with non-small cell lung cancer, where the prevalence of an ALK alteration is 3–5%, would almost certainly fail to detect a clinical signal.3